Emerald Mutual Fund Advisers Trust Trims Position in Insmed Incorporated (NASDAQ:INSM)

Emerald Mutual Fund Advisers Trust trimmed its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 1.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 487,664 shares of the biopharmaceutical company’s stock after selling 6,185 shares during the quarter. Insmed makes up 1.9% of Emerald Mutual Fund Advisers Trust’s investment portfolio, making the stock its 7th largest position. Emerald Mutual Fund Advisers Trust’s holdings in Insmed were worth $35,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Nisa Investment Advisors LLC grew its position in shares of Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 135 shares during the last quarter. CWM LLC grew its position in shares of Insmed by 11.0% in the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the last quarter. Finally, Atomi Financial Group Inc. grew its position in shares of Insmed by 1.4% in the 3rd quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock worth $1,697,000 after buying an additional 314 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. TD Cowen lifted their price objective on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial restated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. Finally, The Goldman Sachs Group lifted their price target on Insmed from $74.00 to $102.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average price target of $83.07.

Insmed Stock Up 1.5 %

INSM stock opened at $68.32 on Friday. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The business has a fifty day moving average price of $73.03 and a 200-day moving average price of $61.51. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The stock has a market capitalization of $11.74 billion, a P/E ratio of -12.31 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same period in the prior year, the company earned ($1.10) EPS. Insmed’s revenue was up 18.1% on a year-over-year basis. Equities analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now owns 67,856 shares in the company, valued at approximately $5,045,093.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock worth $5,765,446 over the last quarter. 4.60% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.